Physiology and pathophysiology of inhibin A and activin A in human pregnancy

Current Opinion in Endocrinology and Diabetes

Volumn 7, Issue 6, 2000, Pages 337-344

  Lambert Messerlian, G ^a  

^a WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; BIOCHEMICAL MARKER; INHIBIN A;

BLOOD LEVEL; CHROMOSOME ABERRATION; DOWN SYNDROME; ECTOPIC PREGNANCY; FEMALE; FETUS WASTAGE; HUMAN; MATERNAL BLOOD; MATERNAL HYPERTENSION; PREECLAMPSIA; PREGNANCY COMPLICATION; PREMATURE LABOR; PRENATAL SCREENING; REVIEW; TISSUE DISTRIBUTION;

EID: 0033667968     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200012000-00008     Document Type: Review

References (109)

1. Advance in the study of inhibin, activin and follistatin production in pregnant women
2. The tissue distribution of activin βA-and βB-subunit and follistatin messenger ribonucleic acids suggests multiple sites of action for the activin-follistatin system during human development
3. Morphological and molecular characteristics of living human fetuses between Carnegie states 7 and 23: Localization of inhibin mRNA alpha and beta A subunits by in-situ hybridization
4. Morphological and molecular characteristics of living human fetuses between Carnegie stages 7 and 23: Immunolocalization of inhibin alpha and beta A subunits
5. Inhibins: Paracrine and endocrine: Effects in female reproductive function
6. Inhibins and activins in human ovulation, conception and pregnancy
7. Influence of non-gonadotrophic hormones on gonadal function
8. Inhibins, activins and follistatins: A review of complex regulators of the reproductive system
9. High concentrations of plasma immunoreactive inhibin during normal pregnancy in women
10. Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassay
11. Measurement of dimeric inhibin B throughout the human menstrual cycle
12. Measurement of serum concentrations of inhibin-A (α-βA dimer) during human pregnancy
13. Measurement of circulating inhibin forms during the establishment of pregnancy
14. A longitudinal study of maternal serum inhibin-A, inhibin-B, activin-A, activin-AB, pro-alphaC and follistatin during pregnancy
15. Changes in dimeric inhibin B concentrations in maternal serum throughout healthy gestation and in women with gestational disease
16. Human follicular fluid contains pro- and C-terminal immunoreactive α-inhibin precursor proteins
17. Biological and immunological characterization of inhibin forms in human follicular fluid and plasma
18. Serum activin A and fellistatin concentrations during human pregnancy a cross-sectional and longitudinal study
19. Changes in peripheral serum levels of total activin A during the human menstrual cycle and pregnancy
20. Influence of age and sex on serum concentrations of total dimeric activin A
21. Identification of naturally occurring follistatin complexes in human biological fluids
22. Inhibin subunits in human placenta: Localization and messenger ribonucleic acid levels during pregnancy
23. Inhibin gene expression in the human corpus luteum
24. Immunohistochemical localisation of inhibin/activin subunits in human placenta
25. Inhibin A and activin A in the first trimester of human pregnancy
26. Measurement of inhibin and activin in early pregnancy: Demonstration of fetoplacental origin and role in prediction of early-pregnancy outcome
27. Source of circulating levels of inhibin A, pro alpha C-containing inhibins and activin A in early pregnancy
28. Inhibin in extra-embryonic coelomic and amniotic fluids and maternal serum in early pregnancy
29. Dimeric inhibins in amniotic fluid, maternal serum, and fetal serum in human pregnancy
30. Inhibin and activin in human fetal membranes: Evidence for a local effect on prostaglandin release
31. Production of inhibin forms by the fetal membranes, decidua, placenta and fetus at parturition
32. Presence and synthesis of inhibin subunits in human decidua
33. Activin A and inhibin B in extra-embryonic coelomic and amniotic fluid and maternal serum in early pregnancy
34. Follistatin and activin A in extra-embryonic coelomic and amniotic fluids and maternal serum in early pregnancy
35. Amniotic fluid concentrations of dimeric inhibins, activin A and follistatin in pregnancy
36. Gonadotropins, prolactin, inhibin A, inhibin B, and activin A in human fetal serum from midpregnancy and term pregnancy
37. The expression of inhibin/activin subunits in the human adrenal cortex and its tumours
38. Antenatal screening for Down's syndrome
39. Endocrine analytes in multiple-marker screening
40. The pattern of maternal serum inhibin-A concentrations in the second trimester of pregnancy
41. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A
42. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy
43. Elevated second-trimester dimeric inhibin A levels identify Down syndrome pregnancies
44. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A
45. Second trimester maternal dimeric inhibin-A in the multiple-marker screening test for Down's syndrome
46. Second trimester levels of maternal serum inhibin A, total inhibin, inhibin precursor, and activin in Down's syndrome pregnancy
47. Prenatal screening for Down's syndrome using inhibin-A as a serum marker
48. Second-trimester dimeric inhibin-A in Down's syndrome screening
49. Second-trimester maternal serum inhibin-A screening for fetal Down syndrome in Asian women
50. Combining inhibin A with existing second-trimester markers in maternal serum screening for Down's syndrome
51. Inhibin A and pro-alpha C inhibin in Down syndrome and normal pregnancies
52. Evolution of an inhibin A ELISA method: Implications for Down's syndrome screening
53. Prospective evaluation of free beta-subunit of human chorionic gonadotropin and dimeric inhibin A for aneuploidy detection
54. Maternal serum inhibin-A levels in twin pregnancies: Implications for screening for Down's syndrome
55. The effect of smoking in pregnancy on maternal serum inhibin A levels
56. Effect of allowing for ethnic group in prenatal screening for Down's syndrome
57. Serum markers for Down's syndrome in women who have had in vitro fertilisation: Implications for antenatal screening
58. Maternal serum inhibin-A in pregnancies complicated by insulin dependent diabetes mellitus
59. Maternal serum inhibin-A in pregnancies with insulin- dependent diabetes mellitus: Implications for screening for Down's syndrome
60. Serum inhibin A levels in pregnant women with systemic lupus erythematosus or antiphospholipid syndrome
61. Maternal serum inhibin-A and free β-hCG concentrations in trisomy 21 pregnancies at 10 to 14 weeks of gestation
62. Evaluation of maternal serum dimeric inhibin-A as a first trimester marker of Down's syndrome
63. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters
64. Biochemistry and endocrinology of the Down's syndrome pregnancy
65. Second trimester levels of maternal serum total activin A and placental inhibin/activin α and βA subunit messenger ribonucleic acids in Down syndrome pregnancy
66. Structure and recombinant expression of human inhibin and activin
67. Maternal serum activin A and follistatin levels in pregnancies with Down syndrome
68. Amniotic fluid inhibin-A in chromosomally normal and Down's syndrome pregnancies
69. Amniotic fluid levels of dimeric inhibins, pro-alpha C inhibin, activin A and follistatin in Down's syndrome
70. Second-trimester maternal serum inhibin A levels in fetal trisomy 18 and Turner syndrome with and without hydrops
71. Inhibin A and non-Down syndrome aneuploidy
72. Maternal serum alpha-fetoprotein and dimeric inhibin A detect aneuploidies other than Down Syndrome
73. Second-trimester maternal serum progesterone levels in Turner syndrome with and without hydrops and in trisomy 18
74. Highly abnormal maternal inhibin and β-human chorionic gonadotropin levels along with severe HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome at 17 weeks' gestation with triploidy
75. Second-trimester pregnancy associated plasma protein-A levels are reduced in Cornelia de Lange syndrome pregnancies
76. Activin A and inhibin A as possible endocrine markers for pre-eclampsia
77. Inhibin-A and pro-alpha C are elevated in preeclamptic pregnancy and correlate with human chorionic gonadotropin
78. Comparison of maternal serum total activin A and inhibin A in normal preeclamptic, and nonproteinuric gestationally hypertensive pregnancies
79. Serum inhibin A levels in women with different types of hypertension in pregnancy
80. Serum activin A and inhibin A elevated in pre-eclampsia: No relation to insulin sensitivity
81. Increased maternal serum activin A but not follistatin levels in pregnant women with hypertensive disorders
82. Prediction of preeclampsia
83. Maternal serum inhibin A can predict preeclampsia
84. Second-trimester maternal serum inhibin A concentration as an early marker for preeclampsia
85. Prediction of pre- eclampsia with maternal mid-trimester total renin, inhibin A, AFP and free beta-hCG levels
86. Second-trimester levels of maternal serum human chorionic gonadotropin and inhibin A as predictors of preeclampsia in the third trimester of pregnancy
87. Raised maternal serum inhibin A concentration at 10 to 14 weeks of gestation is associated with pre-eclampsia
88. Endocrine assays to predict preterm delivery
89. Free activin at parturition: Changes of maternal serum levels and evidence for binding sites in placenta and fetal membranes
90. Abnormal concentration of maternal serum activin-A in gestational diseases
91. Episodic secretion of activin A in pregnant women
92. Activin A, inhibin A, inhibin B and parturition: Changes of maternal and cord serum levels according to the mode of delivery
93. Concentrations of activin A, inhibin A and follistatin in human amnion, choriodecidual and placental tissues at term and preterm
94. High levels of fetal membrane activin beta A and activin receptor IIB mRNAs and augmented concentration of amniotic fluid activin A in women in term or preterm labor
95. Increased midtrimester amniotic fluid activin A: A risk factor for subsequent fetal death
96. Identification of the source of inhibins at the time of conception provides a diagnostic role for them in very early pregnancy
97. Progesterone, inhibin, and hCG multiple marker strategy to differentiate viable from nonviable pregnancies
98. Serum inhibin levels are lower in ectopic than intrauterine spontaneously conceived pregnancies
99. Evaluation of serum inhibin A as a surveillance marker after conservative management of tubal pregnancy
100. Structure and expression of a membrane component of the inhibin receptor system
101. Betaglycan binds inhibin and can mediate functional antagonism of activin signaling
102. Expression patterns of follistatin and two follistatin-related proteins during mouse development
103. Uterine milk protein, a novel activin-binding protein, is present in ovine allantoic fluid
104. Characterization of inhibin/activin subunit, activin receptor and follistatin messenger ribonucleic acid in human and mouse oocytes: Evidence for activin's paracrine signaling from granulosa cells to oocyte
105. Dimeric inhibins and activin A in human follicular fluid and oocyte cumulus culture medium
106. Inhibin suppresses human chorionic gonadotropin secretion in term, but not first trimester, placenta
107. Inhibin and activin modulate the release of gonadotropin-releasing hormone, human chorionic gonadotropin, and progesterone from cultured human placental cells
108. Functional capacity of fetal zone cells of the baboon fetal adrenal gland: A major source of alpha-inhibin
109. Expression and function of activin beta A during mouse cardiac cushion tissue formation